CAMBRIDGE, Mass.--(BUSINESS WIRE)--Boston Pharmaceuticals (the “Company”) today announces the appointment of Joanne Beck, Ph.D., as Chief Operating Officer. Dr. Beck joins Boston Pharmaceuticals from Celgene Corporation, where she was Executive Vice President of Global Pharmaceutical Development and Operations and led the Celgene’s pharmaceutical, biologics and cell therapy technical development, global supply chain and quality operations. At Boston Pharmaceuticals, Dr. Beck will provide leadership and oversight of development strategy and cross-functional operations.
“We are thrilled to welcome Joanne to the leadership team as we transition toward the next stage of growth,” said Robert Armstrong, PhD, Chief Executive Officer & Co-Founder of Boston Pharmaceuticals. “Joanne brings over a decade of experience in pharmaceutical process development and clinical manufacturing across a broad range of therapeutic areas. Her deep expertise in global pharmaceutical operations is a tremendous asset to Boston Pharmaceuticals and will be instrumental in building on our pipeline and success.”
“Boston Pharmaceuticals has made tremendous progress in the past few years and its growth has been acknowledged by the industry,” said Dr. Beck. “I am impressed with the company’s unique strategy of selecting high-value candidates and advancing them through the next appropriate value inflection point. I look forward to leveraging my experience to support the company’s growth at this pivotal time as it continues to advance a diversified portfolio of candidates through the clinic.”
Prior to Celgene, Dr. Beck served as Senior Vice President of Pharmaceutical Development at Shire where she was responsible for CMC development and clinical manufacturing and led the advancement of a diverse product portfolio which included small molecules, proteins, mAbs, Gene Therapy and mRNA therapeutics. Prior to joining Shire, she held leadership positions in Abbott’s Global Pharmaceutical Operations and Abbott Vascular and led. Prior to Abbott, she held positions of increasing responsibility at Genentech’s and Amgen’s Process Development organizations. She holds a Ph.D. in Biochemistry and Molecular Biology from the Oregon Health and Sciences University, a B.A. in Chemistry from Lewis and Clark College and completed Postdoctoral Fellowships at the University of California San Francisco and at Genentech Inc. Dr. Beck serves on the board of directors for Orchard Therapeutics and Catabasis Pharmaceuticals.
About Boston Pharmaceuticals
Boston Pharmaceuticals is a clinical stage biopharmaceutical company that leverages an experienced drug development team to advance a portfolio of high value candidates that address important unmet medical needs. The Company partners with innovative biotechnology and pharmaceutical companies to acquire drug development candidates. We employ unencumbered decision making, follow the data and advance only those programs that meet our stringent development hurdles. Following clinical proof of concept, we establish value creating partnerships with the world’s leading biotechnology and pharmaceutical companies or advance programs through commercialization. We are continuously seeking new opportunities to leverage our model to create a path to value for our partners and patients. For more information, please visit www.bostonpharmaceuticals.com.
